HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wingerchuk, D. M. Articles by Noseworthy, J. H. Search for Related Content PubMed PubMed Citation Articles by Wingerchuk, D. M. Articles by Noseworthy, J. H.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Randomized controlled trials to assess therapies for multiple sclerosis

From the Department of Neurology, Mayo Clinic and Mayo Foundation, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Dr. Noseworthy).

Address correspondence and reprint requests to Dr. John H. Noseworthy, Department of Neurology, Mayo Clinic/Mayo Foundation, 200 First Street, SW, Rochester, MN 55905.

MS poses formidable challenges to clinical investigators. Obstacles to the study of MS therapies include disease chronicity, an unpredictable clinical course, radiologic and pathologic heterogeneity, and limited understanding of the underlying pathophysiology. Randomized controlled trials (RCTs) provide a means to assess therapeutic efficacy while reducing the risks of study bias and confounding factors that influence interpretation of results. RCTs have demonstrated that type 1 interferons and glatiramer acetate alter the short-term natural history of MS and have served as the basis of approval for the marketing of these treatments. Improvements and optimization of trial methodology may hasten the discovery of effective therapies and facilitate better comparisons of the results of individual drug trials. The most urgent need is for improved surrogate end points for clinical outcome with predictive validity for long-term disability. Even if RCT methodology is optimal, however, several limitations inherent to MS trials threaten to impede further progress, including obstacles to long-term studies (e.g., costs), patient withdrawal, and escalating sample size requirements to detect partial therapeutic benefit. There is a crucial need to develop alternative investigative methods, possibly through enhanced collaboration across centers and with industry, and by exploring innovative techniques to use existing RCT and natural history databases to greater advantage.

This article has been cited by other articles:

				C. Bartels, K. Spate, H. Krampe, and H. Ehrenreich Review: Recombinant human erythropoietin: novel strategies for neuroprotective/neuroregenerative treatment of multiple sclerosis Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 193 - 206. [Abstract] [PDF]

				H Butzkueven, J Chapman, E Cristiano, F Grand'Maison, M Hoffmann, G Izquierdo, D Jolley, L Kappos, T Leist, D Pohlau, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 769 - 774. [Abstract] [PDF]

				S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu Regression to the mean in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829. [Abstract] [PDF]

				R. A. Marrie, G. Cutter, T. Tyry, O. Hadjimichael, D. Campagnolo, and T. Vollmer Changes in the ascertainment of multiple sclerosis Neurology, October 11, 2005; 65(7): 1066 - 1070. [Abstract] [Full Text] [PDF]

				A. C Lo, O. Hadjimichael, and T. L Vollmer Treatment patterns of multiple sclerosis patients: a comparison of veterans and non-veterans using the NARCOMS registry Multiple Sclerosis, February 1, 2005; 11(1): 33 - 40. [Abstract] [PDF]

				A. Pacifico and P. D. Henry Ablation for atrial fibrillation: are cures really achieved? J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1940 - 1942. [Abstract] [Full Text] [PDF]

				T. F Scott, C. J Schramke, and G. Cutter Sample size estimates for determining treatment effects in high-risk patients with early relapsing-remitting multiple sclerosis Multiple Sclerosis, June 1, 2003; 9(3): 289 - 292. [Abstract] [PDF]